ArticleBioengineered2022
Protective effects of asiaticoside on renal ischemia reperfusion injury in vivo and in vitro.
Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Asiaticoside alleviates inflammation and intestinal barrier dysfunction in Crohn's disease-like colitis in a manner associated with the RhoA/ROCK/MLC pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Phytocompounds with immunomodulatory activities: mechanisms, therapeutic potential, and clinical prospects.Inflammopharmacology · 2026Review
- Network pharmacology and experimental validation of asiaticoside protecting against diabetic kidney disease by regulating 11β-hydroxysteroid dehydrogenase type 2.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
- Selenium-derived bioactive enablers for advanced therapies: From molecular redox modulation to broad-spectrum disease applications.Bioactive materials · 2026Review
- Plant metabolites: potential treatments for ischemic acute kidney injury.Frontiers in pharmacology · 2026Review
- Long Noncoding RNA SNHG12 Regulates Ischemia/reperfusion (I/R)-mediated Acute Kidney Injury (AKI) Through miR-129-1-3p/Ubiquitin Specific Peptidase 25 axis.Applied biochemistry and biotechnology · 2025Article
- Asiaticoside-Loaded Multifunctional Bioscaffolds for Enhanced Hyperglycemic Wound Healing.Biomedicines · 2025Review
- Protective effects of lupeol in rats with renal ischemia‑reperfusion injury.Experimental and therapeutic medicine · 2024Article
- Annexin-A5 monomer as a membrane repair agent for the treatment of renal ischemia-reperfusion injury.Molecular biology reports · 2024Article
- Comparison of the Antioxidant Potency of Four Triterpenes ofAntioxidants (Basel, Switzerland) · 2024Article
- Circular RNA_HIPK3-Targeting miR-93-5p Regulates KLF9 Expression Level to Control Acute Kidney Injury.Computational and mathematical methods in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemia/reperfusion injury (I/R) is the main causes of acute kidney injury (AKI), which is a global health concern. Evidence suggests that asiaticoside plays vital roles on anti-inflammatory and, anti-kidney fibrosis effects, and promotes tissue repair. However, the effects of asiaticoside on AKI caused by ischemia-reperfusion have not been well defined. Herein, we explored the protective effect of asiaticoside on renal ischemia-reperfusion injury (IRI) using in vivo and in vitro studies, and elucidated the potential mechanism of asiaticoside-mediated repair. Results showed that asiaticoside attenuated the levels of blood urea nitrogen (BUN) and serum creatinine (Scr) in the IRI model. Meanwhile, asiaticoside reduced the secretion of IL-6, IL-1β and TNF-α, but increased IL-10 secretion in a dose-dependent manner. Treating Raw264.7 cells with lipopolysaccharide (LPS) induced an inflammatory response, but the LPS-induced effects were attenuated after administering asiaticoside. Furthermore, asiaticoside significantly inhibited the expression of inducible Nitric Oxide Synthase (iNOS) and promoted the expression of Arginase1 induced by LPS, which are the polarization marker proteins. In conclusion, this study shows that asiaticoside possesses protective action in AKI after ischemia-reperfusion, due to the inhibition of inflammatory mediators and promoting transformation of macrophages from M1 type to M2 type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.